How could you write this article and give no mention of the massive incentive that exists by these drugs receiving permanent and lifetime approvals for Medicare and Medicaid… they’re trying to get Ozempic approved for kids as young as 6 years old … so I don’t buy they’re doing this for the sob story of the founder’s wife. Not to mention …
How could you write this article and give no mention of the massive incentive that exists by these drugs receiving permanent and lifetime approvals for Medicare and Medicaid… they’re trying to get Ozempic approved for kids as young as 6 years old … so I don’t buy they’re doing this for the sob story of the founder’s wife. Not to mention the standard of care for overweight and obesity should be diet and exercise not GLP-1.
Clearly, obtaining Medicare/Medicaid approval for as many indications as possible must be a major goal. Unfortunately, I am not an expert on that system. The Danish Health Authority specify that Wegovy is not first line treatment for obesity, and even those who take it should of course eat healthy and exercise as well. It is no silver bullit, but for some, this drug is a major, life-saving advance.
Look, I’m no expert either, but in an article largely about the critique that Sanders is offering, which hinges on costs to the American health care system (and thus American taxpayers) it seems to be a massive hole in the analysis. The fact still remains that the costs are exponentially higher in the US because of the failure of the US govt and certain rules under the Affordable Care Act that preclude essentially having “price matching”. So, to pharma companies, Medicare and Medicaid is a giant money printer.
As for the standard of care, I think I’d take most developed countries over the US! So I’m not surprised Netherlands is better on the subject and I’m very glad to hear it. That should also tell you something if the country the product is manufactured in has a different standard of care for when the product is used …
As I write in the analysis, I will make no effort to defend the American health care system. You are most likely correct that Medicare/Medicaid should be given better possibility to negotiate prices. Indeed, better regulation of prices during the patent protected period is exactly what I call for. Regulation to ensure these drugs are used for the medically correct purposes and are not indiscriminately prescribed based on patient demand and wishes is also desirable in my opinion
How could you write this article and give no mention of the massive incentive that exists by these drugs receiving permanent and lifetime approvals for Medicare and Medicaid… they’re trying to get Ozempic approved for kids as young as 6 years old … so I don’t buy they’re doing this for the sob story of the founder’s wife. Not to mention the standard of care for overweight and obesity should be diet and exercise not GLP-1.
Clearly, obtaining Medicare/Medicaid approval for as many indications as possible must be a major goal. Unfortunately, I am not an expert on that system. The Danish Health Authority specify that Wegovy is not first line treatment for obesity, and even those who take it should of course eat healthy and exercise as well. It is no silver bullit, but for some, this drug is a major, life-saving advance.
Look, I’m no expert either, but in an article largely about the critique that Sanders is offering, which hinges on costs to the American health care system (and thus American taxpayers) it seems to be a massive hole in the analysis. The fact still remains that the costs are exponentially higher in the US because of the failure of the US govt and certain rules under the Affordable Care Act that preclude essentially having “price matching”. So, to pharma companies, Medicare and Medicaid is a giant money printer.
As for the standard of care, I think I’d take most developed countries over the US! So I’m not surprised Netherlands is better on the subject and I’m very glad to hear it. That should also tell you something if the country the product is manufactured in has a different standard of care for when the product is used …
As I write in the analysis, I will make no effort to defend the American health care system. You are most likely correct that Medicare/Medicaid should be given better possibility to negotiate prices. Indeed, better regulation of prices during the patent protected period is exactly what I call for. Regulation to ensure these drugs are used for the medically correct purposes and are not indiscriminately prescribed based on patient demand and wishes is also desirable in my opinion